Angiosarcoma

News

November 24, 2020

2 min read

Save

Ipilimumab-nivolumab combination effective, safe for angiosarcoma subset

A quarter of patients with unresectable or metastatic angiosarcoma responded to a combination of ipilimumab and nivolumab, according to results of an analysis presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Part of the Healio Network

Cardiac Tumors

There are many different primary cardiac tumors the vast majority of which are benign. The most common malignant cardiac tumor is the angiosarcoma. Cardiac tumors are summarized below: